Jpmorgan Chase & CO Co Diagnostics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Co Diagnostics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 76 shares of CODX stock, worth $62. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76
Previous 76
-0.0%
Holding current value
$62
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CODX
# of Institutions
43Shares Held
4.28MCall Options Held
48.2KPut Options Held
53.3K-
Vanguard Group Inc Valley Forge, PA1.78MShares$1.46 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny568KShares$465,5320.0% of portfolio
-
Black Rock Inc. New York, NY502KShares$411,6600.0% of portfolio
-
Geode Capital Management, LLC Boston, MA321KShares$263,4450.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX273KShares$223,7780.01% of portfolio
About Co-Diagnostics, Inc.
- Ticker CODX
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 33,781,000
- Market Cap $27.7M
- Description
- Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and ...